Previous 10 | Next 10 |
Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc....
Trevi Therapeutics to Present at 11th World Congress on Itch (WCI) PR Newswire NEW HAVEN, Conn. , Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercializ...
Gainers: Nutriband (NTRBW) +84%, Nutriband (OTCQB:NTRB) +38%, Inhibrx (NASDAQ:INBX) +29%, Titan Pharmaceuticals (NASDAQ:TTNP) +14%, Quanterix (NASDAQ:QTRX) +17%. Losers: Organogenesis (NASDAQ:ORGO) -17%, Trevi Therapeutics (NASDAQ:TRVI) -11%,&...
Analysts See Big Upside In These Penny Stocks Whether you’re looking for penny stocks to buy now or ones to add to a watch list, there’s a process involved in finding the best. Of course, a lot will depend on your strategy and outlook on the market. But there are a few bas...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re kicking off the week with a look at the biggest pre-market stock market movers for Monday! Source: f11photo/Shutterstock.com There’s plenty of news moving stock today with ...
Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference PR Newswire NEW HAVEN, Conn. , Oct. 7...
Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis PR Newswire NEW HAVEN, Conn. , Se...
Trevi Therapeutics, Inc. (TRVI) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Bill Forbes - Chief Development Officer Conference Call Participants Serge Belanger - Needham & Company Presentation Opera...
Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Lin...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...